Hostname: page-component-586b7cd67f-rcrh6 Total loading time: 0 Render date: 2024-12-02T20:55:17.216Z Has data issue: false hasContentIssue false
  • English
  • Français

Gamma Knife Radiosurgery for High Grade Glial Neoplasms: A Canadian Experience

Published online by Cambridge University Press:  23 September 2014

F.A. Zeiler ,
A.M. Kaufmann ,
P.J. McDonald ,
D. Fewer ,
J. Butler ,
G. Schroeder  and
M. West
F.A. Zeiler*
Affiliation:
Section of Neurosurgery, Department of Surgery, University of Manitoba, Winnipeg, Manitoba, Canada
A.M. Kaufmann
Affiliation:
Section of Neurosurgery, Department of Surgery, University of Manitoba, Winnipeg, Manitoba, Canada
P.J. McDonald
Affiliation:
Section of Neurosurgery, Department of Surgery, University of Manitoba, Winnipeg, Manitoba, Canada
D. Fewer
Affiliation:
Section of Neurosurgery, Department of Surgery, University of Manitoba, Winnipeg, Manitoba, Canada
J. Butler
Affiliation:
Department of Radiation Oncology, University of Manitoba, Winnipeg, Manitoba, Canada
G. Schroeder
Affiliation:
Department of Radiation Oncology, University of Manitoba, Winnipeg, Manitoba, Canada
M. West
Affiliation:
Section of Neurosurgery, Department of Surgery, University of Manitoba, Winnipeg, Manitoba, Canada
*
Section of Neurosurgery, University of Manitoba, Health Sciences Center, GB-1 820 Sherbrook Street, Winnipeg, Manitoba, R3A 1R9, Canada. Email: [email protected].
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Object:

To review our institutional experience with Gamma Knife (GK) stereotactic radiosurgery in treating focally recurrent high grade glial neoplasms of World Health Organization (WHO) grade III or IV.

Methods:

We conducted a retrospective cohort review of all patients treated with GK for focally recurrent high grade gliomas at our institution between November 2003 and April 2013. Data on age, sex, tumor volume, location and maximal diameter, presenting clinical status, complications and clinical outcome was recorded.

Results:

A total of 33 patients were identified. Four were lost to follow-up. Average post-GK and overall survival was 20.4 months (range: 3 – 72) and 63.3 months (range: 10 – 214) respectively. For WHO grade IV gliomas, the average post-GK and overall survival was 15.8 months (range: 3 – 77) and 40.1 months (range: 13 – 148) respectively. Similarily, for WHO grade III gliomas, the average post-GK and overall survival was 34.9 months (range: 6 – 72) and 136.4 months (range: 22 – 214) respectively. Twenty-two patients (75.9%) had post-GK edema, with 14 requiring dexamethasone and eight being asymptomatic. Four patients (13.8%) had imaging defined radiation necrosis.

Conclusions:

Gamma Knife SRS affords an extension of local tumor control, acceptable morbidity, and potentially prolonged survival, for highly selected patients with focally recurrent high grade glial neoplasms.

Résumé

RÉSUMÉ Objectif:

Le but de l'étude était de revoir notre expérience institutionnelle de la radiochirurgie stétéotaxique par scalpel gamma (SG) pour traiter les récidives de néoplasies gliales de haut grade de malignité, soit de grade III ou IV de l'OMS.

Méthode:

Nous avons effectué une revue rétrospective de cohorte de tous les patients traités par SG pour une récidive focale d'un gliome de haut grade dans notre institution entre novembre 2003 et avril 2013. Nous avons recueilli les informations sur l'âge, le sexe, le volume de la tumeur, sa localisation et son diamètre maximal, l'état clinique du patient au moment de la consultation initiale, les complications et l'issue clinique.

Résultats:

Nous avons identifié 33 patients. Quatre ont été perdus au suivi. La survie moyenne post SG et la survie globale étaient de 20,4 mois (écart : 3 à 72 mois) et 63,3 mois (écart : 10 à 214) respectivement. La survie moyenne post SG et la survie globale étaient de 15,8 mois (écart : 3 à 77 mois) et 40,1 mois (écart : 13 à 148 mois) respectivement. Pour les gliomes de grade III de l'OMS, la survie moyenne post-SG et la survie globale étaient de 34,9 mois (écart : 6 à 72 mois) et 136,4 mois (écart : 22 à 214 mois) respectivement. Vingt-deux patients (75,9%) ont présenté un œdème post SG : 14 d'entre eux ont dû recevoir de la dexaméthasone et 8 étaient asymptomatiques. Quatre patients (13,8%) présentaient une radionécrose à l'imagerie.

Conclusions:

La radiochirurgie stétéotaxique par SG permet de prolonger le contrôle local de la tumeur avec une morbidité acceptable et une prolongation éventuelle de la survie chez des patients choisis avec soin qui présentent une récidive bien localisée d'une néoplasie gliale

Type
Original Article
Information
Canadian Journal of Neurological Sciences , Volume 40 , Issue 6 , November 2013 , pp. 783 - 789
Copyright
Copyright © The Canadian Journal of Neurological 2013

References

1. Niyazi, M, Siefert, A, Scharz, SB, et al. Therapeutic options for recurrent malignant glioma. Radiother Oncol. 2011; 98:1–14.Google Scholar
2. Curran, WJ Jr, Scott, CB, Horton, J, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst. 1993;85(9):704–10.CrossRefGoogle ScholarPubMed
3. Li, J, Wang, M, Won, M, et al. Validation and simplification of the Radiation Therapy Oncology Group recursive partitioning analysis classification for glioblastoma. Int J Radiat Oncol Biol Phys. 2011;81(3):623–30.Google Scholar
4. Stupp, R, Hegi, ME, Mason, WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459–66.Google Scholar
5. Oh, J, Sahgal, A, Sanghera, P, et al. Glioblastoma: patterns of recurrence and efficacy of salvage treatments. Can J Neurol Sci. 2011;38:621–5.Google Scholar
6. Alexiou, GA, Tsiouris, S, Kyritsis, AP, Voulgaris, S, Argyropoulou, MI, Fotopoulos, AD. Glioma recurrence versus necrosis: accuracy of current imaging modalities. J Neurooncol. 2009;95:1–11.Google Scholar
7. Shaw, E, Scott, C, Souhami, L, et al. Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90–05. Int J Radiation Oncol Biol Phys. 2000;47(2):291–8.Google Scholar
8. Hsieh, PC, Chandler, JP, Bhangoo, S, Panagiotopoulos, K, Kalapurakal, JA, Marymont, MH. Adjuvant gamma knife stereotactic radiosurgery at the time of tumor progression potentially improves survival for patients with glioblastoma multiforme. Neurosurgery. 2005;57(4):684–700.Google Scholar
9. Kondziolka, D, Flickinger, JC, Bissonette, DJ, Bozik, M, Lunsford, LD. Survival benefit of stereotactic radiosurgery for patients with malignant glial neoplasms. Neurosurgery. 1997;41(4):776–85.CrossRefGoogle ScholarPubMed
10. Patel, M, Siddiqui, F, Jin, JY, et al. Salvage reirradiation for recurrent glioblastoma with radiosurgery: radiographic response and improved survival. J Neurooncol. 2009;92:185–91.Google Scholar
11. Minniti, G, Scaringi, C, De Sanctis, V, et al. Hypofractionated stereotactic radiotherapy and continuous low-dose temozolomide in patients with recurrent or progressive malignant gliomas. J Neurooncol. 2013;111:187–94.CrossRefGoogle ScholarPubMed
12. Elliot, RE, Parker, EC, Rush, SC, et al. Efficacy of gamma knife radiosurgery for small-volume recurrent malignant gliomas after initial radical resection. World Neurosurg. 2011;76(1/2):128–40.Google Scholar
13. Kong, DS, Lee, JI, Park, K, Kim, JH, Lim, DH, Nam, DH. Efficacy of stereotactic radiosurgery as a salvage treatment for recurrent malignant gliomas. Cancer. 2008;112(9):2046–51.Google Scholar
14. Souhami, L, Sieferheld, W, Brachman, D, et al. Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of radiation therapy oncology group 93–05 protocol. Int J Radiation Oncol Bioly Phys. 2004;60(3):853–60.Google Scholar
15. Skeie, BS, Enger, PO, Bregger, J, et al. Gamma Knife surgery versus reoperation for recurrent glioblastoma multiforme. World Neurosurg. 2012;78(6):658–69.Google Scholar
16. Cox, JD, Stetz, J, Pajak, TF. Toxicity criteria of the radiation therapy oncology group (RTOG) and the European organization for research and treatment of cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31(5):1341–6.CrossRefGoogle ScholarPubMed
17. Mandl, ES, Dirven, CM, Buis, DR, Postma, TJ, Vandertop, WP. Repeated surgery for glioblastoma multiforme: only in combination with other salvage therapy. Surg Neurol. 2008;69:506–9.Google Scholar
18. Wick, A, Felsberg, J, Steinbach, JP, et al. Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. J Clin Oncol. 2007;25:3357–61.Google Scholar
19. Shaw, E, Scott, C, Souhami, L, et al. Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocoal 90–95. Int J Radiat Oncol Biol Phys. 2000;47(2):291–8.Google Scholar
20. Pouratian, N, Crowley, RW, Sherman, JH, Jagannathan, J, Sheehan, JP. Gamma Knife radiosurgery after radioation therapy as an adjunctive treatment for glioblastoma. J Neurooncol. 2009;92:409–18.Google Scholar
21. Kano, H, Niranjan, A, Khan, A, et al. Does radiosurgery have a rolein the management of oligodendrogliomas? J Neurosurg. 2009; 110:564–71.Google Scholar